GC3114高剂量四价流感疫苗在健康成人中的随机单盲I期临床试验
本研究为2017-2018季在19-64岁健康成人中开展的随机、单盲、阳性对照I期临床试验,评估GC3114高剂量四价灭活流感疫苗(HD-QIV)的免疫原性与安全性。结果显示HD-QIV对各毒株血清保护率较高,A/H3N2血清转化率和GMT比值显著高于标准剂量组,未报告严重不良事件。
要点
- HD-QIV对A/H1N1、A/H3N2、B/Yamagata、B/Victoria血清保护率分别为100.0%、96.67%、83.33%、96.67%。
- HD-QIV组A/H3N2血清转化率和GMT比值显著高于标准剂量对照组。
- 未报告严重不良事件,GC3114在健康成人中安全、耐受良好且具免疫原性。
核心结论
- GC3114高剂量四价流感疫苗在19-64岁健康成人中安全、耐受良好且具免疫原性。
研究设计与样本
- 随机、单盲、阳性对照I期临床试验,于2017-2018季在19-64岁健康成人中评估GC3114高剂量四价灭活流感疫苗。
- 对照为标准剂量四价流感疫苗(SD-QIV),临床试验注册号NCT03357263。
主要发现
- HD-QIV组血清保护率:A/H1N1为100.0%,A/H3N2为96.67%,B/Yamagata为83.33%,B/Victoria为96.67%。
- HD-QIV组血清转化率:A/H1N1为86.67%,A/H3N2为90.0%,B/Yamagata为53.33%,B/Victoria为53.33%。
- HD-QIV组接种后/前几何平均滴度比值(GMTR):A/H1N1为15.28,A/H3N2为8.19,B/Yamagata为3.56,B/Victoria为3.03。
- A/H3N2的血清转化率和接种后/前GMTR在HD-QIV组显著高于SD-QIV对照组。
- 未报告严重不良事件。
临床怎么用
- 为高剂量四价流感疫苗在健康成人中的免疫原性和安全性提供了I期临床证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Influenza is a major medically attended respiratory illness. The impact of influenza on morbidity and mortality is particularly high in the elderly. Immunosenescence attenuates the immune response of influenza vaccine in the elderly. High-dose influenza vaccine contains 60 μg of hemagglutinin per strain, four times more compared with standard-dose (SD) influenza vaccine. This study is a phase I clinical trial investigating the immunogenicity and safety of the GC3114, high-dose, quadrivalent inactivated influenza vaccine (HD-QIV) in healthy adults aged 19-64 years during the 2017-2018 season. Seroprotection rates of HD-QIV were 100.0% for A/H1N1, 96.67% for A/H3N2, 83.33% for B/Yamagata, and 96.67% for B/Victoria. Seroconversion rate for A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains were 86.67%, 90.0%, 53.33%, and 53.33%, respectively, in the HD-QIV group. The post-/pre-vaccination geometric mean titer ratio (GMTR) was 15.28 for A/H1N1, 8.19 for A/H3N2, 3.56 for B/Yamagata, and 3.03 for B/Victoria in the HD-QIV group. Seroconversion rate and post-/pre-vaccination GMTR for A/H3N2 were significantly higher in the HD-QIV group than in the SD-QIV group (control). No serious adverse events were reported. In conclusion, GC3114 was safe, well-tolerated, and immunogenic in healthy adults. Clinical Trials Identifier: NCT03357263.
引用
- Noh JY, Jang YS, Lee SN, et al. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults. Vaccine. 2019. PMID: 31377075. doi:10.1016/j.vaccine.2019.07.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。